Endocrinology & Metabolic Syndrome
Open Access
ISSN: 2161-1017
ISSN: 2161-1017
Mina Aziz
Aneurin Bevan University Health Board, United Kingdom
Scientific Tracks Abstracts: Endocrinol Metab Syndr
Introduction: Breast cancer is the most common malignancy affecting women all over the world. In the UK, breast cancer accounts for 15% of all new cancer cases (2016-2018). Breast cancer is the 4th most common cause of cancer death in the UK, accounting for 7% of all cancer deaths (2018). Reporting ER, PR and HER2 receptors in invasive breast cancer cases is very important as it has a powerful predictive value on prognosis. The NICE guidelines recommend reporting these receptors for all invasive breast cancers simultaneously at the time of initial histopathological diagnosis. The aim of this project is to investigate if we are reporting the receptors (ER, PR, and HER2) for all invasive breast cancer patients during the time of discussion of the management options according to the NICE guidelines. Patients and Methods: Baseline data were collected retrospectively over five months period on a sample of 54 cases. Data was collected using the Hospital record system of pathology reports. Results: 54 patients were included in the audit during the five months period. All the 54 patients had ER receptors reported during the MDT discussion (100%), all the 54 patients had HER2 receptors reported during the MDT discussion (100%), 24 patients only had PR receptors reported (44.4%) & in 30 patients, the PR receptors were not reported. Our local trust policy was to report ER and HER2 receptors in all breast cancer patients. In case of ER -ve tumours, PR was then requested. 10 patients had ER-ve tumour, all of them had PR reported. Conclusion: Although NICE guidelines clearly state to “Request the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER2) status of all invasive breast cancers simultaneously at the time of initial histopathological diagnosis [2018], Not reporting PR receptors in all patients, did not affect the overall management plan for our patients.
Mina Aziz is working as a researcher at Aneurin Bevan University Health Board in united kingdom. He is also a trust member in the South Tees Hospital, NHS Foundation trust. He has published many articles in the reputed journals.